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Global governments have committed to achieve Universal Health Coverage (UHC), ensuring access to quality and 
affordable healthcare for all. This is fundamental for those with type 1 diabetes mellitus, who require daily access 
to both insulin and blood glucose test strips to survive. This group risks being left behind by global initiatives that 
fail to consider these particular needs.  
Methods 
A questionnaire was distributed to key informants in 37 less-resourced countries. Seven high-income countries 
were also included for comparison. We drew on a WHO framework developed to assess progress towards UHC to 
create scales on three dimensions: population covered, services provided and direct costs. A fourth dimension, 
availability, was added. Results were grouped into six patterns and visually displayed with radar graphs.  
Results 
65% of the less-resourced national health systems provided insulin, with medians of 67% for service provision 
(equating to Human Regular and NPH), 55% direct costs covered, and 75% availability. Test strips were only 
provided in 14% of the less-resourced systems, with medians 42% (less than two strips per day), 76%, and 88% 
respectively. Six patterns of provision were identified. Progress correlated with income level, yet some low-income 
countries are achieving provision for insulin and test strips for those enrolled in health insurance schemes.  
Conclusion 
No less-resourced country had even near-complete coverage for insulin, and coverage was worse for test strips. 
This study demonstrates the utility of this framework which could be developed as a means of tracking progress 
in meeting the needs of people with diabetes. 
Keywords: Universal Health Coverage, Sustainable Development Goals, Diabetes, Type 1 Diabetes, Insulin, Blood 





People with type 1 diabetes mellitus (T1DM) face severe risks if they cannot access insulin and test strips. Although 
their situations have improved greatly in some countries [1], many still face the prospect of premature death and 
severe complications because of an inability to secure reliable and affordable supplies of these products.[2–8] 
Fortunately, health is now high on the global agenda, with Goal 3 of the United Nations’ Sustainable Development 
Goals calling on governments to ensure healthy lives and promote wellbeing for all at all ages[9] by meeting targets 
including Target 3.4, “reduce by one-third premature mortality from non-communicable diseases through 
prevention and treatment…”[9]; and Target 3.8, “achieve universal health coverage (UHC), including financial risk 
protection, access to quality essential health-care services, and access to safe, effective, quality, and affordable 
essential medicines and vaccines for all”[9].   
These commitments have stimulated numerous initiatives to develop and strengthen health financing and delivery 
systems but there is a risk that the very specific needs of the estimated 425 million people worldwide who have 
diabetes, 80% of whom live in low-and middle-income countries, could be overlooked[10]. Providing diabetes care 
has many challenges, including for instance procuring, storing, and distributing a product such as insulin that 
requires a complex management system, including a cold chain. It has been previously shown that access to crucial 
medical supplies for people with diabetes varies globally.[1,8,11–13]  
Coverage by health services has several dimensions. This is commonly represented by means of a cube (Figure 
1),[14,15] with three dimensions: population covered, services or treatments covered, and share of the direct cost 




A self-assessment questionnaire on sustainability, distributed to diabetes centres supported by the International 
Diabetes Federation Life for a Child Program (LFAC) in 2016-17, was the primary source of data. The instrument 
included a range of questions on aspects of national health systems, and government supply of insulin and test 
strips, and their costs and availabilities in national health systems, private and public retail pharmacies, and health 
insurance schemes. Before distribution it was reviewed by experts in diabetes access in less-resourced countries, 
and was distributed in English, French and Spanish.  
The self-assessment was completed by the senior person in the organization supported by LFAC that provided 
clinical care to young people with diabetes in that country. The self-assessment was distributed to 37 countries: 
Azerbaijan, Bangladesh, Bolivia, Burkina Faso, Burundi, Cambodia, Central African Republic, Democratic Republic 
of Congo, Dominican Republic, Ecuador, Eritrea, Ethiopia, Ghana, Guatemala, Guyana, Haiti, Jamaica, Kenya, 
Liberia, Maldives, Mali, Mauritania, Mexico, Nepal, Nigeria, Pakistan, Philippines, Republic of Congo, Rwanda, Sri 
Lanka, Sudan, Tajikistan, Tanzania, Togo, Uganda, Uzbekistan, and Vietnam. 
Questions included end-user costs of 10mL of insulin (analogue or human long/short acting or pre-mixed insulin 
as applicable) and blood glucose testing strips. Costs were obtained in local currency and then converted to US$ 
at the time. When prices were reported as a range, the lowest value was used for analysis.  When necessary, follow 
up questions were clarified. Information on coverage, provision, costs, and availability was also collected from 
senior diabetes figures in Australia, France, Italy, Japan, New Zealand, Sweden, and the United Kingdom.   
Provision of services was defined as insulin and strips being supplied through the public health system.  Each 
dimension was defined as a percentage as follows: 
Population was defined as the percentage of the population who can potentially access the public health service. 
When health system coverage was not universal, figures were corroborated by published sources where possible.  
Many countries have a variety of health systems, including private insurance schemes used predominantly by the 
wealthy or have services exclusively accessed by certain groups such as armed forces. In this study, we reviewed 
those government health systems in which a substantial proportion of the population was enrolled. For instance, 
two in particular had several systems that each covered a substantial share of the population, with differing 
eligibility and entitlements. Mexico has three large systems: IMSS for private sector employees and dependents 
(enrolment 58.9% of the population), ISSSTE – for public sector employees and dependents (10.6%) and the basic 
national health system Seguro Popular for those not covered by IMSS or ISSTE (44.9%) ( There is some overlap in 
enrolment between the systems). [16]. In Tanzania, the National Health Insurance Fund (NHIF) is mandatory for 
public servants and their dependents[17] and is also available for other workers if they can afford membership 
fees. Enrolment was noted to be 7.2% in 2014[18], with the Tanzanian in-country investigator reporting a rise in 
this figure to 27% in 2017. The remainder of the population have access to the basic national public health system.  
For Services, two empirical scales were developed: for insulin, we used a four point scale, which we expressed as 
a percentage, with the provision of analogue insulin scaled 100%, NPH and regular 67%, pre-mixed only 33.3%, 
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and none 0%; for test strips, provision was expressed on a five point scale as 100% for four or more test strips/day, 
75% for three/day etc., with 0% for no provision. 
Direct cost was calculated as the out of pocket cost people with diabetes pay for services in the public health 
system divided by the costs of those same services when purchased completely out of pocket (retail cost at a 
private pharmacy).  
Availability was estimated by the country correspondent from a scale of 100% being always available, 75% mostly 
available, 50% sometimes available, 25% rarely available, and 0% never available.  
2016 Gross National Income per capita, atlas method (current US$)[19] and World Bank country income level 




Radar graphs were developed in Microsoft Excel to provide a visual representation of provision for insulin and test 
strips in each country.  Provision was represented by shading within an equilateral triangle (Figure 2.) 
The three WHO UHC dimensions were each represented by distance from the middle of the triangle to the 
respective point of the triangle, and the area included was shaded. Then availability, as the fourth dimension, was 
designated by a particular colour of a traffic light system. Green shading indicates 100% availability, light green 
75-100%, amber 50-75%, light red 25-50%, and dark red 0-<25%.  
3. Results 
37 countries returned the self-assessment by January 2018. The geographic distribution was Africa (18 countries), 
Americas (8), Asia (7), Caucasus/Central Asia (3), and Western Pacific (1).  
Respondents included: one mission hospital with the largest type 1 diabetes clinic in the country (Liberia), two 
Ministry of Health contacts (Burundi and Guyana), four senior endocrinologists (Azerbaijan, Ghana, Pakistan, and 
Philippines), five diabetes nongovernmental organisations doing extensive work in diabetes care (Burkina Faso, 
Democratic Republic of Congo, Dominican Republic, Guatemala, and Mali), six government hospitals (Kenya, 
Nepal, Nigeria, Sudan, Tajikistan, and Vietnam), and 19 national diabetes association chiefs (Bangladesh, Bolivia, 
Cambodia, Central African Republic, Ecuador, Eritrea, Ethiopia, Haiti, Jamaica, Maldives, Mauritania, Mexico, 
Republic of Congo, Rwanda, Sri Lanka, Tanzania, Togo, Uganda, and Uzbekistan).  
The self-assessment questionnaire was also completed by diabetes experts in seven High-income countries (HICs) 
in Australia, France, Italy, Japan, New Zealand, Sweden, and the United Kingdom.  
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3.1 Population coverage in Public Health Systems 
All of the less-resourced countries had some form of national public health system. However, due to geographic 
distance or civil disturbance (e.g. Mali), incomplete enrolment in health insurance programs (e.g. Mutuelle de Santé 
in Rwanda, National Health Insurance Fund in Tanzania and National Health Insurance Schemes in Ghana and Kenya), 
use of private health care (e.g. Ecuador), and other reasons, the coverage in the public health sector was less than 
100% in some countries.  
3.2 Services, Cost and Availability 
3.2.1 Insulin 
In the 37 less-resourced countries, 24 (65%) of the profiled health systems provided insulin, with medians of 67% 
service provision and 55% direct costs covered, and 13 (35%) did not. Human pre-mixed insulin only was provided 
in two countries and NPH and regular in 20 countries. Two provided analogue insulin (10 mL 100 IU equivalent) at 
a modest cost (Azerbaijan [$25.00 USD] and Vietnam [$12.18 USD]). For the 24 countries that provided insulin, 
eight covered 100% of the costs, nine part of the costs, and seven none of the costs (Table 1).  Availability ranged 
from 25% in Sri Lanka to 100% in Burundi, Mexico, and Tajikistan (median 75%).  
Although Mexico’s basic health system, Seguro Popular, only provided pre-mixed insulin, the other Mexican health 
systems IMSS and ISSSTE provided NPH insulin to members. The basic public health system in Tanzania provided 
insulin with a 64% subsidy and the NHIF provided NPH insulin free of charge.  
In the 13 countries where governments did not provide insulin, out-of-pocket costs for a 10mL vial of insulin 
ranged from $3.84 to $34.09 (median $9.04, mean $12.55). 
The seven HICs all had 100% coverage through the respective national health system, with co-payments being 











Country Pattern GNI per 






Availability Cost 10 ml. vial 




covered   
Availability Cost of one blood 
glucose test strip 
accessed at private 
pharmacy (USD)  
LESS-RESOURCED COUNTRIES 
Azerbaijan*   N/A $4,760 100%  100% 0% 100% $25.00 3% 100% 100% $0.70 
Bangladesh   6 $1,330 100%  0% N/A N/A $8.61 0% N/A N/A $0.27 
Bolivia ** 6 $3,070 57% 0% N/A N/A $20.28 0% N/A N/A $0.62 
Burkina 
Faso   
6 $640 100%  0% N/A N/A $8.82 0% N/A N/A $0.54 
Burundi  5 $280 100%  67% 25% 100% $8.00 0% N/A N/A $0.38 




6 $370 100%  0% N/A N/A $13.30 0% N/A N/A $1.00 
Congo, 
Dem. Rep.   
6 $420 100%  0% N/A N/A $4.00 0% N/A N/A $0.50  
Congo, Rep.   6 $1,710 100%  0% N/A N/A $3.84 0% N/A N/A $0.32 
Dominican 
Republic   





Ecuador ** 4 $5,820 63% 67% 100% 62.5% $22.00 0% N/A N/A $1.07 
Eritrea   5 N/A 100%  67% 0% 75% $3.43 0% N/A N/A $0.59 






5 $1,380 36%[20] 67% 0% 50% $13.29 
 
0% N/A N/A $1.11 
Guatemala 6 $3,790 100%  0% N/A N/A $34.09 0% N/A N/A $0.48 
Guyana   3 $4,250 100%  67% 100% 90% $20.00 42% 100% 90% $0.48 
Haiti   6 $780 100%  0% N/A N/A $9.25 0% N/A N/A $0.51 







Fund ***  
5 $1,380 13%[21]  67% 40% 75% $9.64 0% N/A N/A $0.58 
Liberia** 6 $370 60% 0% N/A N/A $23.28 0% N/A N/A $1.06  
Maldives**
** 
5 $7,430 78%[22] 67% 100% 50% $20.13 0% N/A N/A $0.71 
Mali** 5 $750 75% 67% 0% 90% $6.59  0% N/A N/A $1.65 





4 $9,040 45%[16] 33% 100% 100% $16.17 0% N/A N/A $0.38 
Mexico 
IMSS***** 
4 $9,040 59%[16] 67% 100% 100% $16.17 0% N/A N/A $0.38 
Mexico 
ISSSTE***** 
4 $9,040 11%[16] 67% 100% 100% $16.17 0% N/A N/A $0.38 
Nepal   6 $730 100%  0% N/A N/A $5.85 0% N/A N/A $0.56 
Nigeria  6 $2,450 30% 0% N/A N/A $7.80 0% N/A N/A $0.56 
Pakistan   4 $1,510 100%  67% 100% 75% $6.13 0% N/A N/A $0.25 




4 $700 75%  67% 90% 75% $8.53 0% N/A N/A $0.37 




5 $2,140 90% 67% 67% 50% $9.00 0% N/A N/A $0.36 






3 $900 27% 67% 100% 100% $6.16 21% 100% 100% $0.88 
Tanzania**  3 $900 73% 67% 64% 100% $6.16 50% 50% 100% $0.88 
Togo   5 $540 100% 67% 0% 75% $7.87 0% N/A N/A $0.54 
Uganda   5 $660 100% 67% 0% 75% $4.71 0% N/A N/A $0.28  
Uzbekistan   4 $2,220 100% 67% 100% 75% $2.97 0% N/A N/A $0.42 
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Vietnam**   5 $2,050 90%  100% 8% 100% $13.23 0% N/A N/A $0.47 
HIGH-INCOME COUNTRIES 
Australia*† 2 $54,420 100% 100% 91% 100% $54.17 100% 76% 100% $0.40 
France* 1 $38,950 100% 100% 100% 100% N/A 100% 100% 100% N/A 
Italy * 1 $31,590 100%  100% 100% 100% N/A 100% 100% 100% N/A 
Japan * 2 $37,930 100%  100% 70% 100% $47.25 100% 70% 100% $0.71 
New 
Zealand*‡ 
2 $39,070 100%  92% 100% 100% N/A 100% 92% 100% N/A 
Sweden* 1 $54,630 100%  100% 100% 100% N/A 100% 100% 100% N/A 
United 
Kingdom*‡̶ 
1 $42,390 100%  100% 100% 100% N/A 100% 100% 100% N/A 
 
* Costs of analogue insulin, not NPH 
**Health system population coverage estimated by in-country investigator 
***Population enrolment in the health service does not include dependents of members 
****Cost of one 3ml cartridge, not 10 ml. vial 
***** Population coverage between Seguro Popular, IMSS, and ISSSTE exceeds 100% due to enrolment overlap between systems. Prices recorded were reported from 
respondents in Nuevo Leon, Mexico. The price situation may vary across Seguro Popular, IMSS, and ISSSTE across other states in Mexico. Respondent noted availability may 
be subject to individual prescribing circumstances. 
† (Australia) Prices as per the National Diabetes Services Schemes (NDSS). There is an annual Safety Net Threshold of 1,138 USD (1,495 AUD).[24]  
‡ (NZ) Assumption based on six vials of testing strips provided at one time for patients on insulin. Prescriptions are regulated by PHARMAC and the fully subsidised analogue 
insulins and test strips are brand-limited. Only one type of test strip is subsidised - an example of competitive bidding.[8] Prescription fees for insulin and test strips are  3.60 
USD (5.00 NZD).[25] After 20 prescriptions in a 12 month period a subsidy permits free prescriptions.[25]  




3.2.2 Test strips 
Only five (14%) of the 37 less-resourced countries provided blood glucose testing strips in their basic health 
systems, with medians of 42% service provision, 76% costs covered, and 88% availability. These included Guyana, 
Dominican Republic, Jamaica, Azerbaijan, and Tanzania.  All, however, had limits on the quantities prescribed and 
entitlements varied.  In Guyana, only young people with T1DM were eligible to receive strips, to a maximum of 50 
per month at no cost, with 90% availability. In the Dominican Republic, public hospitals in the capital provided a 
variable number of strips per day (up to three in some situations) at no cost with good availability. In Jamaica, test 
strips were moderately subsidised (56%) in the public health system, and people with diabetes were eligible to 
access 50 strips per month. However, availability of strips was estimated to be erratic (10% and limited to the 
capital city). In Azerbaijan, 50 strips per year were provided, fully subsidised, and always available.  Test strips 
could be accessed in Tanzania’s basic public health system, where the cost was subsidised 50% and availability 
75%. Tanzania’s NHIF provided 25 strips per month with full availability and no co-payment. 
Out-of pocket costs for one test strip ranged from $0.25 to $1.65 (median $0.49, mean $0.56). 
The seven HICs all had essentially 100% coverage through the respective national health system, with co-payments 
being required in two countries (Table 1). 
3.3 Patterns  










 “Services” – 




“Services” – strips 





100% 100% 100% 100% 100% 100% 100% 
France, Italy, Sweden, United Kingdom 
Pattern 2: 
100% 100% 70-92% 100% 100% 70-92% 100% 
Australia, Japan, New Zealand 
Pattern 3: 
27-100% 67% 64-100% 75-100% 0-42% 50-100% 25-100% 
Dominican Republic, Guyana, Jamaica, 
Tanzania National Health Insurance Fund, 
Tanzania Public Health System 
Pattern 4: 
75-100% 33-67% 90-100% 62.5-100% 0% 0% 0% 
Ecuador, Mexico (Instituto de Seguridad y 
Servicios Sociales de los Trabajadores del 
Estado, Instituto Mexicano del Seguro Social, 
Seguro Popular), Pakistan, Rwanda (Mutuelles 
de Santé), Uzbekistan 
Pattern 5: 
13-100% 33-67% 0-100% 25-100% 0% 0% 0% 
Eritrea, Ethiopia, Ghana, Kenya National 
Health Insurance Fund, Mali, Maldives 
(Aasandha), Philippines, Sri Lanka, Sudan, 





0% 0% 0% 0% 0% 0% 
Bangladesh, Bolivia, Burkina Faso, Cambodia, 
Central African Republic, Democratic Republic 
of Congo, Guatemala, Haiti, Liberia, 




Patterns were defined as: Pattern 1: High population coverage, full provision of insulin and test strips, high 
proportion of direct costs covered, full availability; Pattern 2: High population coverage, full provision of insulin 
and test strips, high proportion of direct costs covered (with some co-payment), full availability; Pattern 3: Variable 
population coverage, mid-range provision of insulin with high proportion of direct costs covered, variable 
availability, limited provision of test strips with half or more of total direct costs covered, variable availability; 
Pattern 4: High population coverage, low to mid-range provision of insulin with high proportion of direct costs 
covered, good availability, no provision of test strips; Pattern 5: Variable population coverage, low to mid-range 
provision of insulin, with either a low proportion of direct costs covered or poor availability or both, no provision 
of test strips; Pattern 6: Medium to high population coverage, no provision of insulin, no provision of test strips.  
Azerbaijan was the only unclassifiable country as its public health system covered a large share of the population, 
yet a wide range of services had to be paid for at full retail costs except for 50 test strips per year.  
3.3.1 Visualisation of extent of UHC  
Representative countries in each pattern were portrayed graphically to show differences in UHC for insulin and 
test strips (Figure 3).  
3.4 Coverage pattern and relationship to country income  
Figure 4 aggregates the coverage patterns of the 36 low-resourced countries (omitting Azerbaijan) and seven HICs, 
by World Bank income level.[19]  
3.5 Other results 
Erratic availability was commonly reported, especially in rural settings. Reported reasons included pharmacy stock 
outs, deriving from logistical problems, cumbersome regulatory procedures, and customs and taxes. Rwanda 
illustrates the problems for rural residents, with few rural pharmacies. When stock-outs occur, patients must travel 
long distances to obtain insulin from private pharmacies, with attendant travel, accommodation, and foregone 
work income costs. 
Respondents from 34 of the less-resourced countries indicated the availability of Private Health Insurance (PHI) 
schemes but all described very low enrolment figures. Only five, in Ecuador, Jamaica, Mali, Sudan, and Togo, 
provided human insulin, with costs even more expensive than when accessed in the public systems, except in Mali 
and Togo where enrolees pay a percentage of the indicative public system cost. Blood glucose test strips were not 
provided in any PHIs.  
Respondents from Azerbaijan and Nepal reported that their respective governments were piloting health 
insurance schemes, but commented that these schemes would only cover diabetes-related hospital admissions, 
not insulin or any other diabetes-related consumable.  
4. Discussion 
This paper presents a framework that can be used to document progress towards meeting the needs of people 
with T1DM at a time when governments are implementing UHC. We apply the framework to 37 low-resourced 
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countries, thereby illustrating the scale and nature of variation, with comparative data from seven high-income 
countries.  
Much research on UHC focuses on financial coverage or access to a small number of specific interventions, such 
as immunisation or access to a skilled birth attendant. However, this provides only an extremely partial picture, 
and as noncommunicable diseases are increasingly prioritised in the international health agenda, it is essential to 
include systems that can monitor the extent to which health systems are responding to T1DM, ensuring that the 
necessary medicines and ancillary products are available and affordable for all. 
We view this paper as proof of principle, rather than a set of definitive results which, ultimately, should be 
obtained from empirical studies. Ideally, these would involve a combination of objective measures, such as facility 
surveys to check price and availability, linked to data on income to assess affordability, complemented with user 
surveys to identify the barriers that people face in obtaining supplies.  
Key Findings 
Six broad patterns of provision were identified.  
All seven high-income countries showed Patterns 1 and 2, with the public health systems providing complete 
coverage and availability, with a modest co-payment in the two Pattern 2 countries (Australia and Japan). As 
income level declined, coverage tended to decrease (Patterns 3-6). This is consistent with published data.[13]  
Health systems in countries showing Patterns 3-5, many of which are low-income, supply varying degrees of insulin 
and test strips. This indicates that some countries have made steps towards achieving coverage of tools needed 
for the management of T1D. These countries provide potential examples for the 13 low and lower-middle income 
countries showing Pattern 6 where there was no government provision.  
Clearly, countries must make difficult choices when resources are constrained. A decision not to provide analogue 
insulin can be justified, as the benefit of the substantially more expensive analogue over a “basal-bolus” human 
insulin regimen is very modest.[27,28] However, access to human short- and long-acting insulin is essential for 
instituting a basal-bolus regimen, which is a cornerstone of modern T1DM care.[29] This regimen cannot be 
delivered with pre-mixed insulin, which was the only insulin provided by two public systems. 
While there are many problems with insulin supply, these are even greater with test strips, with only partial 
provision in five of the 37 less-resourced countries. This is consistent with an earlier LFAC study, which found that 
no public health systems in 37 LMICs and LICs provided test strips.[13] Self-monitoring of blood glucose (SMBG) is 
an essential tool in adequate management of T1DM. Insulin dosages can be adjusted to food and exercise patterns, 
dangerous extremes of blood glucose levels can be avoided entirely or more easily detected[30], and long-term 
complications reduced due to improved glycaemic control.[8,31] The lack of test strip provision is compounded by 
out-of-pocket costs as the purchase of strips can outweigh the costs of daily insulin in many countries.[6]  
A possible contributor to this disparity is that although the WHO has a Essential Diagnostics List that details glucose 
testing, it is not listed for self-management, but only to diagnose and screen for diabetes, intermediate 
hyperglycemia and hypoglycaemia.[32]  
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The results demonstrate that, in addition to the three dimensions of coverage, availability must also be considered 
– entitlement to insulin is meaningless if it is not available. Recognising the limitations of our data, based on self-
report, it is noteworthy that, of the 24 less-resourced health systems that provided insulin, 75% estimated <80% 
availability, with particular problems reported by many countries outside urban centres. These countries have not 
yet reached the voluntary global target of 80% availability of affordable essential medicines required to treat major 
noncommunicable diseases.[33]  
This study focused on insulin and test strips, but comprehensive strengthening of national health systems is 
needed for adequate T1DM care, including skilled health professionals, diabetes education, and inpatient services. 
The WHO ‘building blocks of the health system’ framework is useful in this regard, showing the importance of 
leadership/governance, overall health system financing, the health workforce, information and research, and 
service delivery.[34] 
Some less-resourced countries have created health insurance programs, but as other authors have noted, these 
face several challenges: cost recovery can be difficult, flat-rate premiums result in the most vulnerable and poor 
being unable to access the program, and non-mandatory membership undermines revenue generation and risk-
pooling.[35] A full discussion of these issues is beyond this paper, however we note three indicative examples.  
The NHIF in Tanzania, which provides insulin and test strips, is compulsory for employees and their families and it 
is also offered to other workers and youth. For government workers, yearly fees amount to 6% of an employee’s 
annual salary per year (split by employee and employer)[17], with 17% of the population enrolled. The Mutuelles 
de Santé in Rwanda has means-tested fees. 75% of the population was enrolled in 2015[36], and human insulin 
was subsidised, with fair availability. Enrolled patients contributed a 10% co-payment plus prescription fees. 
However, there was no coverage for strips. In Ghana’s NHIS, 40% of the population was enrolled in 2016 and end-
users funded annual enrolment fees through social security contributions and premium payments[37], but insulin 
was frequently not available and strips were not covered.  
In theory, private health insurance programs could potentially help people with T1DM who could afford the 
premiums, if those premiums were community rather than risk-related and if other barriers to recruitment were 
eliminated. However, the finding that these private schemes do not appear to cover outpatient medication costs, 
beyond those in a few countries that offer human insulin only, is of concern. The ongoing expense to someone 
with a chronic disease should be addressed.  
Finally, the radar graphs/triangles compiled in this study can readily be used to document progress being made in 
coverage of those with other diseases.  
Study limitations 
This study has some obvious limitations. Firstly, the data were obtained from a single investigator in each country, 
and thus we were unable to compare national estimates on population, services, and costs. However, the country 
investigators were all experts responsible for organising care for young people with diabetes in their countries and 
thus were able to provide a broad assessment of national context. Their assessments were intended to cover the 
overall national, rather than just the region where the respondent was located, and were based on his or her self-
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assessment and expert judgement, and at a single point in time. Additionally, indirect costs, including 
transportation or absenteeism, associated with accessing insulin or test strips were not taken into consideration. 
Finally, this survey only includes a sample of high-income countries and it excludes the USA. It, almost uniquely 
among high income countries does not provide universal coverage and its prices of insulin are very much higher 
than in comparable countries. Hence, it is widely considered an extreme outlier in international comparisons. 
Moreover, given the unique complexity of the US health system, with multiple payers and delivery schemes, it 
would be misleading to provide summary statistics. 
The results of this study clearly cannot be expected to provide a definitive and comprehensive assessment of 
patterns of price and availability. However, we hope that the framework we propose could become the basis of a 
system to monitor progress in the ability to manage diabetes, and thereby contribute to UHC.  The next steps 
should include development of an agreed methodology, such as that used in the WHO/Health Action International 
Project on Medicine Prices and Availability,[38] that could be applied regularly in a range of countries to provide 
empirical, accurate, and representative data to monitor progress. This should also include measures that capture 
the actual financial burden falling on people living with diabetes related to their income, also including the coping 
strategies that they and their family members engage in[39], and recognising the barriers they often face in obtaining 
employment. In this respect, and while not claiming the same ambition, we note how the 2000 World Health 
Report[40], on assessing health systems performance, also suffered from many data gaps but stimulated a major 
effort that has led to a vast improvement of the available information worldwide. 
5. Conclusion 
There is great variation in health system coverage of insulin and test strips in less-resourced countries. Provision 
is inadequate in all countries studied, and the situation is worse for test strips than for insulin. Until there is a 
system in place to monitor and ensure that both insulin and test strips are both provided to all who need them, 
by equitable health systems at affordable prices, Goal 3 of the Sustainable Development Goals cannot be realised 
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